Acquisition Context IMARC was acquired by Avania in June 2021, signaling a broader integration into a leading medical device CRO. This presents a sales opportunity to align with Avania’s expanded capabilities and cross-sell IMARC’s services to Avania’s existing client base and partners.

Regulatory Readiness Specializes in guiding clinical researchers toward FDA and global approvals with emphasis on compliance, auditing, and training. Target pharma and device sponsors seeking efficient, cost-effective trial management and site readiness solutions.

Quality and Compliance Focus Led by a dedicated Quality Assurance leadership appointment in 2018 and ongoing emphasis on quality initiatives. Opportunities to upsell enhanced QA services, audits, and process improvements to improve trial integrity and minimize risk for sponsors.

Mid-market Footprint Employee count and revenue place IMARC in the mid-market segment, suggesting reach to mid-sized biotechnology and medical device sponsors who need specialized CRO support without large-tier agency pricing.

Growth through Partnerships Presence in the US with strong site management and training offerings indicates potential collaborations with regional sites and networks, as well as opportunities to package ongoing monitoring, training, and compliance programs for ongoing trial support.